Search Results - "Yang, Michael B"

Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity by Wallace, David K, Kraker, Raymond T, Freedman, Sharon F, Crouch, Eric R, Bhatt, Amit R, Hartnett, M Elizabeth, Yang, Michael B, Rogers, David L, Hutchinson, Amy K, VanderVeen, Deborah K, Haider, Kathryn M, Siatkowski, R Michael, Dean, Trevano W, Beck, Roy W, Repka, Michael X, Smith, Lois E, Good, William V, Kong, Lingkun, Cotter, Susan A, Holmes, Jonathan M

“…Intravitreous bevacizumab (0.25 mg to 0.625 mg) is commonly used to treat type 1 retinopathy of prematurity (ROP), but there are concerns about systemic…”
Get more information

Length of Day during Early Gestation as a Predictor of Risk for Severe Retinopathy of Prematurity by Yang, Michael B., MD, Rao, Sujata, PhD, Copenhagen, David R., PhD, Lang, Richard A., PhD

“…Purpose Fetal mice require light exposure in utero during early gestation for normal vascular development in the eye. Because angiogenic abnormalities in…”
Get full text

Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity by VanderVeen, Deborah K., MD, Melia, Michele, ScM, Yang, Michael B., MD, Hutchinson, Amy K., MD, Wilson, Lorri B., MD, Lambert, Scott R., MD

“…Purpose To review the available evidence on the ocular safety and efficacy of anti-vascular endothelial growth factor (VEGF) agents for the treatment of…”
Get full text

Periocular Tissue Concentrations of Propranolol after Ocular Instillation of a Gel-Forming Solution by Yang, Michael B, Liu, Hongzhuo, Li, S Kevin, Hao, Jinsong

“…The aim of this study was to determine the concentrations of propranolol in periocular tissues and plasma after ocular instillation of 0.5% propranolol…”
Get more information

Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology by VanderVeen, Deborah K, Melia, Michele, Yang, Michael B, Hutchinson, Amy K, Wilson, Lorri B, Lambert, Scott R

“…To review the available evidence on the ocular safety and efficacy of anti-vascular endothelial growth factor (VEGF) agents for the treatment of retinopathy of…”
Get full text

A direct and melanopsin-dependent fetal light response regulates mouse eye development by Rao, Sujata, Chun, Christina, Fan, Jieqing, Kofron, J. Matthew, Yang, Michael B., Hegde, Rashmi S., Ferrara, Napoleone, Copenhagen, David R., Lang, Richard A.

“…During retinal vascular development there is simultaneous regression of the hyaloid vasculature and formation of the retinal vasculature; here it is…”
Get full text

Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study by Wallace, David K, Kraker, Raymond T, Freedman, Sharon F, Crouch, Eric R, Hutchinson, Amy K, Bhatt, Amit R, Rogers, David L, Yang, Michael B, Haider, Kathryn M, VanderVeen, Deborah K, Siatkowski, R Michael, Dean, Trevano W, Beck, Roy W, Repka, Michael X, Smith, Lois E, Good, William V, Hartnett, Mary Elizabeth, Kong, Lingkun, Holmes, Jonathan M

“…Intravitreous bevacizumab (0.25 to 0.625 mg) is increasingly used to treat type 1 retinopathy of prematurity (ROP), but there remain concerns about systemic…”
Get more information

Detection of Clinically Significant Retinopathy of Prematurity Using Wide-angle Digital Retinal Photography by Chiang, Michael F., MD, Melia, Michele, ScM, Buffenn, Angela N., MD, MPH, Lambert, Scott R., MD, Recchia, Franco M., MD, Simpson, Jennifer L., MD, Yang, Michael B., MD

“…Objective To evaluate the accuracy of detecting clinically significant retinopathy of prematurity (ROP) using wide-angle digital retinal photography. Methods…”
Get full text

Clinical Models and Algorithms for the Prediction of Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology by Hutchinson, Amy K, Melia, Michele, Yang, Michael B, VanderVeen, Deborah K, Wilson, Lorri B, Lambert, Scott R

“…To assess the accuracy with which available retinopathy of prematurity (ROP) predictive models detect clinically significant ROP and to what extent and at what…”
Get full text

Risk analysis and an alternative protocol for reduction of screening for retinopathy of prematurity by Yang, Michael B., MD, Donovan, Edward F., MD

“…Purpose To determine whether a multivariate risk model can select infants with low-risk eyes for an alternative protocol that reduces retinopathy of…”
Get full text

Surgical Outcomes Following Repair of Traumatic Retinal Detachments in Cognitively Impaired Adolescents With Self-Injurious Behavior by Sisk, Robert A, Motley, 3rd, W Walker, Yang, Michael B, West, Constance E

“…Purpose: To assess anatomic outcomes following repair of traumatic retinal detachment (RD) among a cohort of cognitively impaired adolescents with…”
Get full text

Treatment of non–type 1 retinopathy of prematurity in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) study by Liu, Tianyu, Tomlinson, Lauren A., Ying, Gui-shuang, Yang, Michael B., Binenbaum, Gil

“…To determine the prevalence and characteristics of eyes treated for retinopathy of prematurity (ROP) not meeting currently recommended early treatment (type 1)…”
Get full text

Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort by Fisher, Kristen S., Gill, Jason, Todd, Hannah F., Yang, Michael B., Lopez, Michael A., Abid, Farida, Lotze, Timothy, Shah, Veeral S.

“…In autoimmune myasthenia gravis (MG), autoantibodies target the neuromuscular junction. Ocular myasthenia gravis (OMG) is localized, affecting only extraocular…”
Get full text

Detection of Clinically Significant Retinopathy of Prematurity Using Wide-angle Digital Retinal Photography: A Report by the American Academy of Ophthalmology by CHIANG, Michael F, MELIA, Michele, BUFFENN, Angela N, LAMBERT, Scott R, RECCHIA, Franco M, SIMPSON, Jennifer L, YANG, Michael B

“…To evaluate the accuracy of detecting clinically significant retinopathy of prematurity (ROP) using wide-angle digital retinal photography. Literature searches…”
Get full text

Variable Anterior Segment Dysgenesis and Cardiac Anomalies Caused by a Novel Truncating Variant of FOXC1 by Ahmed, Mariya R, Sethna, Saumil, Krueger, Laura A, Yang, Michael B, Hufnagel, Robert B

“…Anterior segment dysgenesis (ASD) encompasses a wide spectrum of developmental abnormalities of the anterior ocular segment, including congenital cataract,…”
Get full text

Retinopathy of prematurity in infants with birth weight ≥ 1250 grams—incidence, severity, and screening guideline cost-analysis by Yang, Michael B., MD

Get full text

Nonlinear association of average day length during early gestation with severe retinopathy of prematurity outcome by Yang, Michael B

Get full text

Rebound tonometry in children: a report by the American Academy of Ophthalmology by Lambert, Scott R, Melia, Michele, Buffenn, Angela N, Chiang, Michael F, Simpson, Jennifer L, Yang, Michael B

“…To compare intraocular pressure (IOP) measurements in children 18 years of age and younger using rebound tonometry and applanation tonometry and the…”
Get full text

Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity by Wallace, David K., Hercinovic, Amra, Freedman, Sharon F., Crouch, Eric R., Bhatt, Amit R., Hartnett, M. Elizabeth, Yang, Michael B., Rogers, David L., Hutchinson, Amy K., Good, William V., Repka, Michael X., Li, Zhuokai, Beck, Roy W., Kraker, Raymond T., Cotter, Susan A., Holmes, Jonathan M.

“…To report 2-year ocular and developmental outcomes for infants receiving low doses of intravitreal bevacizumab for type 1 retinopathy of prematurity (ROP). A…”
Get full text

Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients by Rice, Melissa L., Wong, Brenda, Horn, Paul S., Yang, Michael B.

“…To evaluate the development of cataracts or elevated intraocular pressure (IOP) in patients with Duchenne muscular dystrophy (DMD) on long-term glucocorticoid…”
Get full text